Patritumab deruxtecan in HR⁺HER2^- advanced breast cancer: a phase 2 trial.

Analysis of PFS according to HER3-membrane expression showed a trend toward a slightly longer PFS in patients with HER3-membrane positivity >75% (median(m)PFS 10.9 months (95% CI [8.2–17.7 months]) or with HER3-membrane H -score >200 (mPFS 10.9 months (95% CI [8.51 months–N/A]) compared with those with the lowest HER3-membrane scoring (mPFS 8.1 months (95% CI [4.4 months–N/A]) in HER3-membrane positivity <25%; mPFS 6.7 (95% CI [5.3 months–N/A]) in HER3-membrane H -score 0–100) (Extended Data Fig. 1 ).

also in 53,322 other papers

Therefore, although this association did not reach statistical significance, potentially due to the small sample size, and does not allow for the definition of a clear HER3 expression threshold, it remains a promising finding that warrants further investigation.

also in 111,027 other papers

This study would also provide an opportunity to further validate the preliminary findings, suggesting a positive trend between HER3-enriched populations and PFS, which helps to refine patient selection strategies.

also in 11,005 other papers